Marex Group’s Neurocrine Biosciences NBIX Stock Holding History

Marex Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$648K	Buy	4,920 +768	+18%	+$102K	﹤0.01%	558
2025 Q4	$589K	Buy	4,152 +2,209	+114%	+$320K	﹤0.01%	516
2025 Q3	$273K	Buy	+1,943	New	+$263K	﹤0.01%	649
2025 Q2	–	Sell	-2,111	Closed	-$233K	–	841
2025 Q1	$233K	Buy	+2,111	New	+$267K	﹤0.01%	541
2024 Q4	–	Sell	-1,764	Closed	-$203K	–	778
2024 Q3	$203K	Buy	+1,764	New	+$242K	﹤0.01%	480

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group's NBIX Position: Q1 2026 in Review

Marex Group increased its Neurocrine Biosciences (NBIX) stake by 18% in Q1 2026, buying an estimated $102K and bringing the position to 4,920 shares worth $648K. The position accounts for ﹤0.01% of the portfolio, ranked #558.

Marex Group first reported a position in NBIX in Q3 2024 and has held it in 5 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Marex Group held 4,920 shares of Neurocrine Biosciences worth $648K as of Q1 2026.
Marex Group bought 768 Neurocrine Biosciences shares in Q1 2026, an estimated $102K.
Neurocrine Biosciences made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #558 holding.
Marex Group first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 5 quarters since.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.